0001415889-24-021194.txt : 20240813
0001415889-24-021194.hdr.sgml : 20240813
20240813170005
ACCESSION NUMBER: 0001415889-24-021194
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240812
FILED AS OF DATE: 20240813
DATE AS OF CHANGE: 20240813
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ferguson Matthew
CENTRAL INDEX KEY: 0001304079
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39577
FILM NUMBER: 241202665
MAIL ADDRESS:
STREET 1: C/O FOXHOLLOW TECHNOLOGIES, INC.
STREET 2: 740 BAY ROAD
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ELUTIA INC.
CENTRAL INDEX KEY: 0001708527
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 474790334
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12510 PROSPERITY DRIVE
STREET 2: SUITE 370
CITY: SILVER SPRING
STATE: MD
ZIP: 20904
BUSINESS PHONE: 240-247-1143
MAIL ADDRESS:
STREET 1: 12510 PROSPERITY DRIVE
STREET 2: SUITE 370
CITY: SILVER SPRING
STATE: MD
ZIP: 20904
FORMER COMPANY:
FORMER CONFORMED NAME: AZIYO BIOLOGICS, INC.
DATE OF NAME CHANGE: 20170605
4
1
form4-08132024_050801.xml
X0508
4
2024-08-12
0001708527
ELUTIA INC.
ELUT
0001304079
Ferguson Matthew
C/O ELUTIA INC.
12510 PROSPERITY DRIVE, SUITE 370
SILVER SPRING
MD
20904
false
true
false
false
CHIEF FINANCIAL OFFICER
0
Class A Common Stock
2024-08-12
4
M
0
50000
A
307823
D
Class A Common Stock
2024-08-12
4
F
0
17840
2.84
D
289983
D
Restricted Stock Units
2024-08-12
4
M
0
50000
0
D
Class A Common Stock
50000
0
D
Transaction represents shares of the Issuer's Class A Common Stock received from the vesting of restricted stock units.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Shares withheld by the Issuer to satisfy tax withholding requirements on vesting of restricted stock units.
On January 31, 2024, the Reporting Person was granted 50,000 restricted stock units. The restricted stock units vested on the 10th business day following the clearance by the U.S. Food & Drug Administration ("FDA") of the Company's CanGarooRM antibiotic-eluting biologic envelope, unless such date is not during one of the Company's open trading windows, in which case such RSUs vested as of the first business day of the next open trading window. The CanGarooRM antibiotic-eluting biologic envelope, now known as EluPro, was cleared by the FDA on June 14, 2024 and the first business day of the next open trading window was August 12, 2024.
/s/ Jeffrey Hamet, Attorney-in-Fact for Matthew Ferguson
2024-08-13